August 1, 2013
Astellas Pharma and FibroGen of the US announced on July 31 that a PII clinical study of the renal anemia treatment ASP1517/FG-4592 has started in Japan for the treatment of anemia associated with chronic kidney disease (CKD) in patients on...read more